JP2023517236A5 - - Google Patents

Info

Publication number
JP2023517236A5
JP2023517236A5 JP2022554815A JP2022554815A JP2023517236A5 JP 2023517236 A5 JP2023517236 A5 JP 2023517236A5 JP 2022554815 A JP2022554815 A JP 2022554815A JP 2022554815 A JP2022554815 A JP 2022554815A JP 2023517236 A5 JP2023517236 A5 JP 2023517236A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
variable region
chain variable
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020843 external-priority patent/WO2021183359A1/en
Publication of JP2023517236A publication Critical patent/JP2023517236A/ja
Publication of JP2023517236A5 publication Critical patent/JP2023517236A5/ja
Pending legal-status Critical Current

Links

JP2022554815A 2020-03-09 2021-03-04 抗コロナウイルス抗体および使用の方法 Pending JP2023517236A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062987313P 2020-03-09 2020-03-09
US62/987,313 2020-03-09
US202063010999P 2020-04-16 2020-04-16
US63/010,999 2020-04-16
US202063030530P 2020-05-27 2020-05-27
US63/030,530 2020-05-27
US202063036089P 2020-06-08 2020-06-08
US63/036,089 2020-06-08
US202063080351P 2020-09-18 2020-09-18
US63/080,351 2020-09-18
US202063085042P 2020-09-29 2020-09-29
US63/085,042 2020-09-29
US202063116483P 2020-11-20 2020-11-20
US63/116,483 2020-11-20
PCT/US2021/020843 WO2021183359A1 (en) 2020-03-09 2021-03-04 Anti-coronavirus antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2023517236A JP2023517236A (ja) 2023-04-24
JP2023517236A5 true JP2023517236A5 (cg-RX-API-DMAC7.html) 2024-03-13

Family

ID=73835506

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554810A Pending JP2023517234A (ja) 2020-03-09 2020-12-09 抗コロナウイルス抗体および使用の方法
JP2022554815A Pending JP2023517236A (ja) 2020-03-09 2021-03-04 抗コロナウイルス抗体および使用の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022554810A Pending JP2023517234A (ja) 2020-03-09 2020-12-09 抗コロナウイルス抗体および使用の方法

Country Status (14)

Country Link
US (5) US20210292393A1 (cg-RX-API-DMAC7.html)
EP (2) EP3878862A3 (cg-RX-API-DMAC7.html)
JP (2) JP2023517234A (cg-RX-API-DMAC7.html)
KR (2) KR102535195B1 (cg-RX-API-DMAC7.html)
CN (2) CN116096742A (cg-RX-API-DMAC7.html)
AU (2) AU2020435452A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022017986A2 (cg-RX-API-DMAC7.html)
CA (2) CA3171237A1 (cg-RX-API-DMAC7.html)
GB (1) GB2593023A (cg-RX-API-DMAC7.html)
IL (2) IL296224A (cg-RX-API-DMAC7.html)
MA (1) MA52390A (cg-RX-API-DMAC7.html)
MX (2) MX2022011142A (cg-RX-API-DMAC7.html)
TW (2) TWI782366B (cg-RX-API-DMAC7.html)
WO (2) WO2021183195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3063952T3 (en) * 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
AU2021225827B2 (en) * 2020-02-24 2024-12-19 Institute Of Microbiology, Chinese Academy Of Sciences Humanized monoclonal antibody for 2019 novel coronavirus and use thereof
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
PH12022553106A1 (en) * 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
US20220003779A1 (en) * 2020-07-03 2022-01-06 The Research Foundation For The State University Of New York Methods for qualitative and quantitative analysis of a plurality of biomarkers
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
US20250263468A1 (en) * 2020-07-24 2025-08-21 Celltrion Inc. Binding molecule having neutralizing activity against coronavirus superfamily
WO2022035918A1 (en) * 2020-08-11 2022-02-17 Eli Lilly And Company Anti-sars-cov-2 antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
PE20231507A1 (es) * 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
WO2022082217A1 (en) 2020-10-16 2022-04-21 Eureka Therapeutics, Inc. Compositions for preventing or treating viral and other microbial infections
WO2022162587A1 (en) * 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CN115141270A (zh) * 2021-03-29 2022-10-04 深圳市康麦生物技术有限公司 特异性结合新型冠状病毒的抗体
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
JP2024518335A (ja) * 2021-04-26 2024-05-01 アンスティチュ パスツール SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
CN113461810B (zh) * 2021-05-17 2021-12-28 深圳市福田区格物智康病原研究所 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用
EP4341289A1 (en) * 2021-05-18 2024-03-27 Christian-Albrechts-Universität zu Kiel Co-stimulatory multispecific antibodies
CN117897173A (zh) * 2021-06-08 2024-04-16 伊莱利利公司 含有2019新型冠状病毒抗体的药物制剂
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023285620A2 (en) * 2021-07-14 2023-01-19 Alchemab Therapeutics Ltd. Compositions and methods for targeting viral proteins
US12600764B2 (en) 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
CN113735969B (zh) * 2021-09-20 2023-05-12 中国人民解放军军事科学院军事医学研究院 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
EP4413122A4 (en) * 2021-10-07 2026-04-08 Seqirus Pty Ltd ANTI-SARS-CoV-2 ANTIBODIES AND THEIR USES I
US20240425567A1 (en) * 2021-10-08 2024-12-26 Invivyd, Inc. Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof
US20240327505A1 (en) * 2021-10-22 2024-10-03 University Of Vermont And State Agricultural College Antibodies to coronavirus sars-cov-2
WO2023076419A2 (en) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Sars-cov-2 antibodies and methods of use
WO2023079137A1 (en) * 2021-11-05 2023-05-11 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
US20250034234A1 (en) * 2021-11-09 2025-01-30 Rhode Island Hospital Predicting covid-19 antibodies among survivors with deep rna sequencing
WO2023084055A1 (en) * 2021-11-12 2023-05-19 Rq Biotechnology Limited Compositions
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
EP4183800A1 (en) * 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
CN116217711A (zh) * 2021-12-03 2023-06-06 广东菲鹏生物有限公司 一种SARS-CoV-2检测方法和试剂盒
KR102793620B1 (ko) 2021-12-09 2025-04-09 한국화학연구원 사스-코로나바이러스-2 뉴클레오캡시드 단백질에 대한 단클론 항체 및 이의 용도
WO2023133338A2 (en) * 2022-01-10 2023-07-13 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240137083A (ko) * 2022-01-28 2024-09-19 에베크 인코포레이티드 변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편
US20250145691A1 (en) * 2022-02-15 2025-05-08 Board Of Regents, The University Of Texas System Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2023159316A1 (en) * 2022-02-28 2023-08-31 Immune Biosolutions Inc. Formulation of anti-sars-cov-2 neutralizing antibodies and uses thereof
US20260035438A1 (en) * 2022-03-04 2026-02-05 The Scripps Research Institute Human broadly neutralizing antibodies against betacoronaviruses
WO2023178182A1 (en) * 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
CN115286712B (zh) * 2022-03-18 2024-09-27 北京百普赛斯医学检验实验室有限公司 新型冠状病毒Delta突变株特异性抗体及其应用
WO2023183848A2 (en) * 2022-03-25 2023-09-28 The Rockefeller University Anti-sars-cov-2 antibodies and methods of use thereof
EP4505179A4 (en) * 2022-04-01 2026-06-24 Invivyd Inc Anti-SARS-CoV-2 antibodies and their uses
CN114656555B (zh) * 2022-04-08 2024-03-19 广州医科大学附属第一医院(广州呼吸中心) 抗SARS-CoV-2病毒的中和抗体及其制备方法和应用
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
WO2024025940A1 (en) * 2022-07-26 2024-02-01 Ap Biosciences, Inc. Sars-cov-2 antibodies and bispecific antibodies
CN116143910B (zh) * 2022-10-12 2026-03-24 水木未来(北京)科技有限公司 靶向SARS-CoV-2刺突蛋白的纳米抗体及其应用
KR20250122456A (ko) * 2022-11-01 2025-08-13 프로비던스 헬스 앤드 서비시즈 - 오레곤 Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
WO2024133564A1 (en) 2022-12-21 2024-06-27 National University Of Singapore Sars-cov-2 spike protein-binding molecules
WO2024187177A2 (en) * 2023-03-09 2024-09-12 The Johns Hopkins University Recombinant antibody for the treatment of extracellular dna overload
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
WO2025222126A1 (en) * 2024-04-19 2025-10-23 Vanderbilt University Var2csa antibodies and methods of use thereof
WO2025255012A1 (en) * 2024-06-03 2025-12-11 Uct Bioscience Co., Ltd. Anti-grp78 antibody, immunoconjugate and uses thereof
US20260144885A1 (en) * 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323840B1 (en) 1999-09-17 2001-11-27 Cts Corporation Surface-mount pointing device
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1644414B1 (en) 2003-07-22 2015-01-14 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
ES2384497T3 (es) 2005-02-08 2012-07-05 The New York Blood Center, Inc. Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
CN114456272A (zh) * 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
EP3892297A1 (en) 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN112300375B (zh) * 2020-11-06 2022-10-25 江苏三木化工股份有限公司 一种水性光固化环氧丙烯酸树脂的制备方法

Similar Documents

Publication Publication Date Title
EP3129047B1 (en) Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
US11591406B2 (en) Treatment for multiple myeloma (MM)
JP2021527640A5 (cg-RX-API-DMAC7.html)
EP3360896B1 (en) Antibody to hepatitis b surface antigen and use thereof
US8093360B2 (en) Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
JP2024507118A5 (cg-RX-API-DMAC7.html)
JP2024109776A (ja) 脊髄損傷及び疼痛を処置するための抗RGMa(Repulsive Guidance Molecule A)アンタゴニスト抗体
JP2025521565A (ja) 補体が媒介する疾患を処置するための方法
EP3463463A1 (en) Combination of cd33 antibody drug conjugates with chemotherapeutic agents
JP2023537078A (ja) COVID-19を治療及び防止するためのSARS-CoV-2抗体
JP2024500322A (ja) 併用療法
JP2023546504A5 (cg-RX-API-DMAC7.html)
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
CN112996540A (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
RU2020141137A (ru) Антитела к коронавирусу и способы применения
AU2023281751A1 (en) Cancer treatment with a pd-1 or pd-l1 inhibitor and an antibody-drug conjugates targeting claudin 18.2
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
US20220267432A1 (en) Method for treating autoimmune disease by il-17 antagonist
JP2019505516A (ja) インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法
JP2023539736A5 (cg-RX-API-DMAC7.html)
TW202547886A (zh) 用於治療c1s介導的疾病和病症的組成物、劑量和方法
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
TW202233230A (zh) 抗-sema3a抗體及其用於治療視網膜栓塞疾病之用途
HK1247939A1 (en) Treatment for multiple myeloma (mm)